Literature DB >> 7714721

Liposomes as in-vivo carriers for citicoline: effects on rat cerebral post-ischaemic reperfusion.

M Fresta1, G Puglisi, C Di Giacomo, A Russo.   

Abstract

Citicoline is a therapeutic agent widely used in the treatment of brain injury, for example in cerebrovascular disease or traumatic accidents. Unfortunately, the strong polar nature of this drug prevents it crossing the blood-brain barrier. In this paper, the possibility of efficiently trapping citicoline in liposomes to improve its therapeutic effects is reported. The citicoline-encapsulation efficiency, drug leakage and size analysis of various liposome systems were studied. The real therapeutic effectiveness of these citicoline liposome formulations was evaluated by biological assay. The effects of free and liposome encapsulated citicoline on survival rate of ischaemic reperfused male Wistar rats (80-100 g) were investigated. Of the phospholipid mixtures used in citicoline liposome formulation the best in terms of delivery and therapeutic effects was 1,2-dipalmitoyl-sn-glycero-phosphocholine: dipalmitoyl-DL-alpha-phosphatidyl-L-serine:cholesterol (7:4:7 molar ratio). This phospholipid mixture was also assayed for brain conjugated diene levels in rats, since this parameter is an index of lipid peroxidation in rat cerebral cortex during post-ischaemic reperfusion. A citicoline-loaded phospholipid mixture has produced an increase in rat survival rate of about 24% and a reduction in diene levels of 60%, compared to the free drug.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7714721     DOI: 10.1111/j.2042-7158.1994.tb03252.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  12 in total

1.  CDP-choline liposomes provide significant reduction in infarction over free CDP-choline in stroke.

Authors:  Rao Muralikrishna Adibhatla; J F Hatcher; K Tureyen
Journal:  Brain Res       Date:  2005-10-05       Impact factor: 3.252

2.  Reduction of maturation phenomenon in cerebral ischemia with CDP-choline-loaded liposomes.

Authors:  M Fresta; G Puglisi
Journal:  Pharm Res       Date:  1999-12       Impact factor: 4.200

Review 3.  Nanoparticle transport across the blood brain barrier.

Authors:  Andreas M Grabrucker; Barbara Ruozi; Daniela Belletti; Francesca Pederzoli; Flavio Forni; Maria Angela Vandelli; Giovanni Tosi
Journal:  Tissue Barriers       Date:  2016-02-25

4.  Intracellular accumulation of ofloxacin-loaded liposomes in human synovial fibroblasts.

Authors:  M Fresta; A Spadaro; G Cerniglia; I M Ropero; G Puglisi; P M Furneri
Journal:  Antimicrob Agents Chemother       Date:  1995-06       Impact factor: 5.191

5.  Enhanced therapeutic effect of cytidine-5'-diphosphate choline when associated with GM1 containing small liposomes as demonstrated in a rat ischemia model.

Authors:  M Fresta; E Wehrli; G Puglisi
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

6.  Stroke: Treatment for acute stroke--the end of the citicoline saga.

Authors:  Wayne M Clark; Tegan D Clark
Journal:  Nat Rev Neurol       Date:  2012-08-07       Impact factor: 42.937

Review 7.  Multifunctional actions of approved and candidate stroke drugs.

Authors:  Jens Minnerup; Wolf-Rüdiger Schäbitz
Journal:  Neurotherapeutics       Date:  2009-01       Impact factor: 7.620

8.  Citicoline protects brain against closed head injury in rats through suppressing oxidative stress and calpain over-activation.

Authors:  Ke Qian; Yi Gu; Yumei Zhao; Zhenzong Li; Ming Sun
Journal:  Neurochem Res       Date:  2014-04-02       Impact factor: 3.996

9.  Effect of Treatment with Cyanidin-3-O-β-D-Glucoside on Rat Ischemic/Reperfusion Brain Damage.

Authors:  Claudia Di Giacomo; Rosaria Acquaviva; Rosa Santangelo; Valeria Sorrenti; Luca Vanella; Giovanni Li Volti; Nicolantonio D'Orazio; Angelo Vanella; Fabio Galvano
Journal:  Evid Based Complement Alternat Med       Date:  2012-09-13       Impact factor: 2.629

Review 10.  Liposomes and nanotechnology in drug development: focus on neurological targets.

Authors:  Pedro Ramos-Cabrer; Francisco Campos
Journal:  Int J Nanomedicine       Date:  2013-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.